影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展

doi:10.11904/j.issn.1002-3070.2020.06.010

摘要/Abstract

摘要： 在世界范围内,乳腺癌是女性发病率最高的恶性肿瘤,也是女性因癌症死亡的主要原因。新辅助化疗(Neoadjuvant chemotherapy,NAC)可以降低乳腺癌分期、缩小肿瘤,甚至使病灶达到病理完全缓解(Pathological complete response,pCR),在乳腺癌综合治疗中得到广泛应用。由于患者对治疗的反应各有差异,所以及时准确评估NAC疗效已成为临床医生关注并致力解决的重点。常规影像学检查手段如乳腺钼靶、超声、PET-CT和磁共振成像(MRI)已广泛用于乳腺癌NAC疗效的评估,且每种影像学检查各有优势和不足。本文就常规影像学检查用于预测乳腺癌患者预后及NAC疗效的研究进展进行综述。

关键词: 乳腺癌, 新辅助化疗, 钼靶, 超声, 磁共振成像, PET-CT

Abstract: Breast cancer is the most common malignancy tumor with the highest incidence of female in the world,and it is also the main cause of female death due to cancer.Neoadjuvant chemotherapy(NAC)can reduce the stage of breast cancer,shrink the tumor,and even make the lesions reach pathological complete response(pCR),and it is widely used in the comprehensive treatment of breast cancer.Because patients have different response to treatment,the timely and accurate evaluation of NAC efficacy has become the focus of clinicians′ attention and efforts to solve.Routine imaging examination methods such as mammography(MG),ultrasound,PET-CT and magnetic resonance imaging(MRI)have been widely used to evaluate the efficacy of NAC in breast cancer,and each imaging examination has advantages and disadvantages.This article reviews the research progress of routine imaging examination for predicting the prognosis of breast cancer patients and the efficacy of NAC.

Key words: Breast cancer, Neoadjuvant chemotherapy, Mammography, Ultrasound, Magnetic resonance imaging, PET-CT

中图分类号:

R737.9

刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.

LIU Hong, LU Hailing, CAI Li. Advances in imaging prediction of prognosis and neoadjuvant chemotherapy response in breast cancer patients[J]. Journal of Practical Oncology, 2020, 34(6): 535-539.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.06.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I6/535

参考文献

1 Waldrep AR,Avery EJ,Rose FF,et al.Breast cancer subtype influences the accuracy of predicting pathologic response by imaging and clinical breast exam after neoadjuvant chemotherapy[J].Anticancer Res,2016,36(10):5389-5395.
2 De Vita R,Pozzi M,Zoccali G,et al.Skin-reducing mastectomy and immediate breast reconstruction in patients with macromastia[J].J Exp Clin Cancer Res,2015,34:120.
3 Matsuda N,Kida K,Ohde S,et al.Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy[J].Breast Cancer,2018,25(1):43-49.
4 Brackstone M,Palma D,Tuck AB,et al.Concurrent neoadjuvant chemotherapy and radiation therapy in locally advanced breast cancer[J].Int J Radiat Oncol Biol Phys,2017,99(4):769-776.
5 Li J,Song Y,Xu S,et al.Predicting underestimation of ductal carcinoma in situ:a comparison between radiomics and conventional approaches[J].Int J Comput Assist Radiol Surg,2019,14(4):709-721.
6 Theberge I,Vandal N,Guertin MH,et al.The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women′s characteristics:is it the same?[J].Breast Cancer Res Treat,2019,174(2):525-535.
7 Zhang Y,Ma AD,Jia HX.Correlation between molybdenum target mammography signs and pathological prognostic factors of breast cancer[J].J Biol Regul Homeost Agents,2016,30(1):219-225.
8 Park J,Chae EY,Cha JH,et al.Comparison of mammography,digital breast tomosynthesis,automated breast ultrasound,magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy[J].Eur J Radiol,2018,108:261-268.
9 Prati R,Minami CA,Gornbein JA,et al.Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy[J].Cancer,2009,115(6):1194-1198.
10 Tadayyon H,Sannachi L,Gangeh MJ,et al.A priori prediction of neoadjuvant chemotherapy response and survival in breast cancer patients using quantitative ultrasound[J].Sci Rep,2017,7:45733.
11 Xu P,Yang M,Liu Y,et al.Breast non-mass-like lesions on contrast-enhanced ultrasonography:feature analysis,breast image reporting and data system classification assessment[J].World J Clin Cases,2020,8(4):700-712.
12 Wan CF,Liu XS,Wang L,et al.Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy[J].Eur J Radiol,2018,103:118-123.
13 郝秀秀,王暘,李岩密,等.多模式超声检查技术在乳腺癌化疗后病情改善程度预测中的应用研究[J].中国医学装备,2018,15(12):82-85.
14 Wang H,Yan B,Yue L,et al.The diagnostic value of 3D power doppler ultrasound combined with VOCAL in the vascular distribution of breast masses[J].Acad Radiol,2020,27(2):198-203.
15 Humbert O,Cochet A,Coudert B,et al.Role of positron emission tomography for the monitoring of response to therapy in breast cancer[J].Oncologist,2015,20(2):94-104.
16 Jung SY,Kim SK,Nam BH,et al.Prognostic impact of ¹⁸F-FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy[J].Ann Surg Oncol,2010,17(1):247-253.
17 Connolly RM,Leal JP,Goetz MP,et al.TBCRC 008:early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer[J].J Nucl Med,2015,56(1):31-37.
18 Groheux D,Hindie E,Marty M,et al.¹⁸F-FDG-PET/CT in staging,restaging,and treatment response assessment of male breast cancer[J].Eur J Radiol,2014,83(10):1925-1933.
19 Groheux D,Giacchetti S,Delord M,et al.Prognostic impact of ¹⁸F-FDG-PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer[J].Eur J Nucl Med Mol Imaging,2015,42(3):377-385.
20 Hulikal N,Gajjala SR,Kalawat T,et al.Predicting response to neoadjuvant chemotherapy using 18F FDG PET-CT in patients with locally advanced breast cancer[J].Asian Pac J Cancer Prev,2020 21(1):93-98.
21 Cho N,Im SA,Cheon GJ,et al.Integrated(18)F-FDG PET/MRI in breast cancer:early prediction of response to neoadjuvant chemotherapy[J].Eur J Nucl Med Mol Imaging,2018,45(3):328-339.
22 Hatt M,Groheux D,Martineau A,et al.Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer[J].J Nucl Med,2013,54(3):341-349.
23 Lee SJ,Chung MS,Shin SJ,et al.Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer[J].Medicine,2018,97(43):e12840.
24 Molina-Garcia D,Garcia-Vicente AM,Perez-Beteta J,et al.Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate[J].Ann Nucl Med,2018,32(6):379-388.
25 Li H,Yao L,Jin P,et al.MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer:a systematic review and meta-analysis[J].Breast,2018,40:106-115.
26 Rauch GM,Adrada BE,Kuerer HM,et al.Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer[J].AJR Am J Roentgenol,2017,208(2):290-299.
27 Jiang Y,Li Y,Fang S,et al.The role of MALAT1 correlates with HPV in cervical cancer[J].Oncol Lett,2014,7(6):2135-2141.
28 Tudorica A,Oh KY,Chui SY,et al.Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI[J].Transl Oncol,2016,9(1):8-17.
29 Tahmassebi A,Wengert GJ,Helbich TH,et al.Impact of machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer patients[J].Invest Radiol,2019,54(2):110-117.
30 Xie T,Zhao Q,Fu C,et al.Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging[J].Eur Radiol,2019,29(5):2535-2544.
31 Le-Petross HT,Lim B.Role of MR imaging in neoadjuvant therapy monitoring[J].Magn Reson Imaging Clin N Am,2018,26(2):207-220.
32 Montemezzi S,Camera L,Giri MG,et al.Is there a correlation between 3T multiparametric MRI and molecular subtypes of breast cancer?[J].Eur J Radiol,2018,108:120-127.
33 赵文芮,许茂盛,王世威,等.DCE-MRI及DWI影像特征对乳腺癌病理组织学分级及Ki-67表达的预测研究[J].中国生物医学工程学报,2019,38(2):176-183.
34 黎玉娇,尚乃舰.影像学评估新辅助化疗反应的研究进展[J].实用肿瘤学杂志,2018,32(1):63-67.
35 马德晶,逯峰,张虎,等.IVIM-DWI模型各参数与乳腺癌预后因子及分子亚型的相关性分析[J].滨州医学院学报,2019,42(5):349-352.
36 Kim Y,Kim SH,Lee HW,et al.Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer[J].Magn Reson Imaging,2018,48:27-33.
37 Che S,Zhao X,Ou Y,et al.Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer[J].Medicine,2016,95(4):e2420.

[1]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[2]	袁瑶, 周显礼. 乳腺癌超声特征与腋窝淋巴结转移相关性的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 576-580.
[3]	左婷婷, 吴颖, 董首兰, 曲宁, 高岿然, 李梦丹, 刘运泳. 辽宁省沈阳市城市地区2016-2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2020, 34(5): 387-390.
[4]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[5]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[6]	刘思奇, 边娜娜, 苏亚娟. 超声BI-RADS联合血CA15-3和CEA在乳腺肿物诊断中的价值研究[J]. 实用肿瘤学杂志, 2020, 34(4): 347-351.
[7]	张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.
[8]	陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.
[9]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[10]	秦凯, 程熠, 袁响林, 简丹妮, 张菁, 黄乐. 超声膀胱容量监测技术在宫颈癌术后调强放疗中的应用价值[J]. 实用肿瘤学杂志, 2020, 34(3): 232-236.
[11]	谢艺才, 高健全. 动态增强MRI成像在鼻咽癌诊疗中的应用价值[J]. 实用肿瘤学杂志, 2020, 34(3): 258-261.
[12]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[13]	赵云霞, 牛波. LncRNA NBAT1通过调控miR-3664-5p/Caspase 9分子轴对人乳腺癌细胞增殖的影响[J]. 实用肿瘤学杂志, 2020, 34(1): 24-29.
[14]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[15]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.